ArticleMaterials today. Bio2026
Glucose-responsive "sense-and-treat" microneedle patch for promoting diabetic chronic wound healing.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic chronic wound, plagued by hyperglycemia-driven oxidative stress, bacterial infection, and impaired angiogenesis, represent a critical biomedical challenge with limited treatment options and dire clinical outcomes. Herein, a glucose-responsive "sense-and-treat" microneedle (MN) patch was designed for on-demand drug release and comprehensive diabetic chronic wound therapy. The multifunctional MN patch (denoted EAG-MNs patch) was fabricated from two functional precursors. Solution A was consisted of phenylboronic acid modified gelatin (PBA-Gel) complexed with epigallocatechin gallate (EGCG) through dynamic boronic ester bonds to provide glucose responsiveness. Solution B contained silver nanoparticle-decorated graphene oxide (AgGO) dispersed in hyaluronic acid (HA) to enable sustained antibacterial action. Upon exposure to hyperglycemic wound microenvironment, the boronic ester bonds undergo dissociation, triggering the rapid release of EGCG to scavenge reactive oxygen species, alleviate inflammation, and promote angiogenesis. Simultaneously, the dissolved AgGO component ensures robust and long-lasting antibacterial activity against prevalent pathogens. In an infected diabetic mouse wound model, the EAG-MNs patch significantly accelerated wound closure, reduced granulation tissue formation, enhanced collagen deposition and vascularization, and effectively eliminated bacterial infection compared to control groups. This intelligent MNs platform exemplifies a novel "sense-and-treat" paradigm for diabetic chronic wound management by actively sensing pathological cues and executing synergistic therapeutic actions, offering a promising versatile strategy for advanced wound care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.